AbbVie has presented two-year data of Skyrizi (risankizumab) showing complete clearance in patients suffering from plaque psoriasis. Skyrizi is indicated for the treatment of plaque psoriasis in adults and has recently received the approval from European Medicines Agency.
About IMMhance study (Phase 3):
The drug was administered in two phases.
Results: 73% achieved skin clearance, 100% improvement in Psoriasis Area Severity Index was achieved in 72% patients compared to 2% of patients who withdrew the treatment.